|
||||
Wednesday, 17 November 2004 - 9:25 AM
0941
Commercial development of attract and kill for control of horticultural pests
A recent approach, Attract and Kill (A&K) has been developed. This technique uses a semiochemical, such as a pheromone or host\feeding attractant, in combination with an insecticide. Thus, when the attracted animal contacts the lure they succumb to the toxic effects of the insecticide. This approach has the obvious advantages of limiting any potential negative ecological effects of the insecticide while accomplishing the immediate removal of the target organism from the population. The application of this robust control technology to horticultural pest management will be presented from a commercial viewpoint.
Species 1: Lepidoptera Tortricidae Cydia pomonella (codling moth)
Species 2: Lepidoptera Pyralidae Acrobasis nuxvorella (pecan nut casebearer)
Species 3: Lepidoptera Tortricidae Cryptophlebia leucotreta (false codling moth)
Keywords: attracticide
![[ Recorded presentation ]](/static/img/filetypes/16x16/wrf.gif){kind=small}
Recorded presentation 
Recorded presentation
See more of Symposium: Attract and Kill Strategies in Insect Pest Management
See more of Symposia
See more of The 2004 ESA Annual Meeting and Exhibition
COMMENTS AND CORRECTIONS
- From Myles Stewart-Hesketh, Mr., SireneCall Pty Ltd, October 17, 2005
Dear Philipp, I was pleased to learn that you were still involved in "Attract-and-Kill". How is the "Last Call" business going in the US? We now own the BayerCrop Science technology, which is vastly superior to that of Syngenta (less expensive, 12-week coverage). However, we own the brand name SIRENE in most markets. We are now selling into most Middle East and Asian markets and are presently developing a version for the blowfly (in conjunction with a US pharmaceutical company) for the ANZ and South African market. We hope to move into the US market in 2006. When I write "we", I mean CS Liew and me (with a couple of minority shareholders). CS's Pacific Agriscience (now Pacific Biotechnology, of which I am a director/ shareholder) is going extremely well. We are a significant shareholder in a Seattle pharmaceutical company (with state-of-art rDNA technology) which we expect to list on NASDAQ in early 2006. This will be our base for the US market (generics, Sirene and other patented products). With best regards. Myles Stewart-Hesketh